Cipla introduces Serroflo for respiratory treatment in Germany and Sweden

India-based Cipla has introduced Serroflo (salmeterol/fluticasone MDI) in Germany and Sweden to treat patients suffering from asthma.

Serroflo is expected to improve the affordability of fixed combinations in Europe and help manage health costs for respiratory treatment.

Cipla Europe head Frank Pieters said: “With Serroflo, we offer in Germany and Sweden an alternative, which is effective and efficient and therefore brings many advantages into a market, which suffers from limited resources.”

The new product is available under the name Serroflo in Germany, while it is introduced as Salmeterol/Fluticasone Cipla in Sweden.

http://www.pharmaceutical-technology.com/news/newscipla-introduces-serroflo-respiratory-treatment-germany-and-sweden-4360899?WT.mc_id=DN_News

Cipla’s shares have vaulted to a record high after the launch of first of its combination inhalers in Germany and Sweden that marked its entry into Europe. Analysts say the launch will lead to a gradual rerating of the stock of the drug maker which has been underperforming its peers.

Read more at:
http://economictimes.indiatimes.com/articleshow/41645849.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst